Disulfidptosis is a novel cell death mode in which the accumulation of
disulfide bonds in
tumor cells leads to cell disintegration and death. Long-stranded noncoding RNAs (LncRNAs) are aberrantly expressed in
hepatocellular carcinoma (HCC) and have been reported to carry significant potential as a
biomarker for HCC prognosis. However,
lncRNA studies with disulfidptosis in
hepatocellular carcinoma have rarely been reported. Therefore, this study aimed to construct a risk prognostic model based on the disulfidptosis-related
lncRNA and investigate the mechanisms associated with disulfidptosis in
hepatocellular carcinoma. The clinical and transcriptional information of 424 HCC patients was downloaded from The
Cancer Genome Atlas (TCGA) and divided into test and validation sets. Furthermore, 1668 lncRNAs associated with disulfidptosis were identified using Pearson correlation. Six
lncRNA constructs were finally identified for the risk prognostic model using one-way Cox proportional hazards (COX), multifactorial COX, and lasso regression. Kaplan-Meier (KM) analysis, principal component analysis, receiver operating characteristic curve (ROC), C-index, and column-line plot results confirmed that the constructed model was an independent prognostic factor. Based on the disulfidptosis risk score, risk groups were identified as potential predictors of immune cell infiltration, drug sensitivity, and
immunotherapy responsiveness. Finally, we confirmed that
phospholipase B domain containing 1
antisense RNA 1 (PLBD1-AS1) and muskelin 1
antisense RNA (MKLN1-AS) were highly expressed in
hepatocellular carcinoma and might be potential
biomarkers in HCC by KM analysis and quantitative real-time PCR (RT-qPCR). This study demonstrated that
lncRNA related to disulfidptosis could serve as a
biomarker to predict prognosis and treatment targets for HCC.